Skip to content
NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP

Tonix Pharmaceuticals Holding Corp. TNXP

18 fiscal years on record · USD · FY2025 reported · SEC filings only
$13.1M
▲ 29.8% YoY
$-124.0M
$-103.2M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

In addition to TONMYA, we market two FDA-approved prescription products for the treatment of acute migraine: Zembrace® SymTouch® (sumatriptan injection) and Tosymra® (sumatriptan nasal spray). Zembrace SymTouch (sumatriptan injection) 3 mg is a low-dose autoinjector designed for ease of use and rapid onset of action. We are developing TNX-1900 (intranasal potentiated oxytocin) for several CNS disorders through investigator-initiated studies.

Written from the business description in Tonix Pharmaceuticals Holding Corp.'s annual report to the U.S. Securities and Exchange Commission, filed 12 March 2026. Every sentence was checked against that document before publication.

Growth

USD 13.1M
Revenue, FY2025 · full 18-year series below
Revenue $M Net income $M
FY2025 · Revenue 13.1 · Net income -124.0
-50M-100M
2008201120142017202020232025
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

−946 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -959.1% · Net -946.2%
-500%-1000%-1500%
200820162025
ROE
FY2025 · ROE -64.5%
-100%-200%
200820162025
Three returns, three denominators.
Gross margin49.3%
Operating margin-959.1%
Net margin-946.2%
EBITDAUSD -123.8M

Each USD of equity lost 64 cents this year.

Cash & shareholders

USD 0.00
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -103.2
-100M-200M
200820162025
Net buybacks $M Dividends $M
FY2025 · Dividends · · Net buybacks -224.2
-100M-200M
20232025

Total assetsUSD 277.2M
EquityUSD 245.2M
CashUSD 207.6M
Current ratio7.42×

Equity funds 88% of total assets.

The 18-year record

18 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
TNXP, 18-year financial record
Metric 202520242023202220212020201920182017201620152014201320122011201020092008
Revenue $B0.00.00.0◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌
Operating income $B−0.1−0.1−0.1−0.1−0.1−0.1−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0◌◌
EBITDA $B−0.1−0.1−0.1−0.1−0.1−0.1−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0◌◌
Income tax $B◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌
Net income $B−0.1−0.1−0.1−0.1−0.1−0.1−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Free cash flow $B−0.1−0.1−0.1−0.1−0.1−0.1−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0◌◌
EPS, diluted $−14.57−176.60−14720.25−20.01−8.10−0.55−19.33−259.85−31.69−15.41−28.62−2.77−3.37−5.58−3.24−0.18◌◌
Dividend / sh $◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌
Payout % — not applicable: no dividend——————————————————
ROE %−64.5−106.1−74.6−51.8−60.2−104.0−173.0−108.1−84.5−118.4−125.9−129.6−291.4—————
Shares out B0.010.000.000.080.500.210.010.000.010.000.020.010.010.000.030.02◌◌

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 65 reconciliationsAUDITED

Reconciled in 18 of the 18 fiscal years we could check. 16 checks were skipped: revenue is not tagged before 2023. Six checks were skipped: the balance sheet is not tagged before 2010. Four checks were skipped: the share count is not tagged before 2011.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inNevada
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2008

Share this section

Download image